Breast Cancer Clinical Trials in Pittsburgh

Showing 181-200 of 717 trials

MARGetuximab Or Trastuzumab (MARGOT)

NCT04425018

The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: * Paclitaxel, Pertzumab and Margetuximab (Margenza) * Paclitaxel, Pertzumab and Trastuzumab (Herceptin)

Breast CancerStage II Breast CancerStage III Breast Cancer+1 more

Dana-Farber Cancer Institute174 participantsStarted Jul 2020

Washington D.C., District of Columbia, United States • Washington D.C., District of Columbia, United States • Boston, Massachusetts, United States +11 more locations

Active Not RecruitingPhase 177 miles

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

NCT03589339

The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.

RadiotherapyImmunotherapyMicrosatellite Instability-High Solid Malignant Tumour+8 more

Nanobiotix145 participantsStarted Jan 2019

San Francisco, California, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +10 more locations

MARGetuximab Or Trastuzumab (MARGOT)

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Breast Cancer Trials in Other Cities

Study of AVZO-021 in Patients With Advanced Solid Tumors

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

A Study of PF-06873600 in People With Cancer

A Study of LY3484356 in Women With Breast Cancer Before Having Surgery

Mirai-MRI: Validation of AI Models for Breast Cancer Risk

Other Conditions in Pittsburgh